Gemopharm Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Location

Moscow Russia

Primary Industry

Pharmaceuticals

About

Based in Moscow, Russia, Gemopharm develops drugs for myeloma patients using antibodies such as Hemofarm, an antibody with an anti-tumor activity and low toxicity.

Current Investors

Primer Capital

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Website

www.gemopharm.ru

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin

31 Dec 2016

31 Dec 2017

20,000,000

6,000

1,000

31 Dec 2018

11,000,000

(45%)

(12,597,000)

(114.5%)

(12,597,000)

(114.5%)

(12,597,000)

(114.5%)

31 Dec 2019

2,000,000

(81.8%)

1,264,000

63.2%

1,264,000

63.2%

1,209,000

60.4%

31 Dec 2020

(100%)

(775,000)

31 Dec 2021

31 Dec 2022

31 Dec 2023

Unlock the recent years of financials and more for Gemopharm.

Request a demo to see more.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.